NCT00506389 - A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707) | Biotech Hunter

Enrollment

419

Participants

Timeline

Start Date

June 6, 2007

Primary Completion Date

February 13, 2008

Study Completion Date

February 13, 2008

Conditions

Insomnia

Interventions

DRUG

Esmirtazapine

Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.

DRUG

Placebo

The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.